New Paradigm in Cerebrovascular Analysis Technology

World's First MRA-based Cerebrovascular Wall Shear Stress Analysis Software
Global Leader in Cerebrovascular Wall Shear Stress Diagnostic Tools

Clinical Research

A Broad Clinical Research Network (Seoul National University Hospital, Samsung Medical Center, Ajou University Hospital, Chonbuk National University Hospital, etc.)

Distribution

Development and Distribution of New Cerebral Hemodynamic Biomarkers

Project Development

Conducting Research Based on SIG Implementation and Clinical Effectiveness in Medical Settings

Our Network

Building and Expanding Healthcare Networks to Support Future Research and Development

mobile background

Innovation in Cerebrovascular Anailsis, MEDIIMG

A Global Leader in Cerebrovascular Analysis Technology, Pioneering the Future of Healthcare with innovative Diagnostic Solutions.

Innovation in Cerebrovascular Analysis,
MEDIIMG

A Global Leader in Cerebrovascular Analysis Technology,

Pioneering the Future of Healthcare with Innovative Diagnostic Solutions.

mobile background
About NeuFlow

NeuFlow is a biomarker program that enables accurate and efficient cerebrovascular disease diagnosis through wall shear stress analysis based on TOF MRA imaging. 

"We provide an easy, intuitive,

and fast process. "

빠른 측정
Quick Measurement

Measurement possible through TOF MRA only, without unnecessary settings

정량데이터 산출
Quantitative Data Output

Statistical-based clinical research enabled. Applicable for various disease factors

사용 편이 제고
Enhanced User Convenience

Eliminates the need for advanced expertise, unlike traditional methods

NeuFlow 3D Color MRA, Innovation in Cerebrovascular Diagnosis

With the world’s first FDA-approved color MRA technology, NeuFlow goes beyond traditional 2D black-and-white imaging—offering precise cerebrovascular health diagnostics through 3D color imaging and quantitative data, along with personalized health guidance. 

NeuFlow 처리 이미지
원본 MRA 이미지
Use NeuFlow
original
Learn more

3D Color SIG
Quantitative Analysis

The conventional black-and-white MRA is converted into 3D color imaging for hemodynamic analysis.

Vessel-specific
precision measurement

Comprehensive analysis using vessel diameter and length measurements along with hemodynamic data.

AI Health Report

Offers a cerebrovascular health score along with personalized health recommendations.

A New Standard
in Brain Health.
Experience NeuFlow.
Quick Measurement
Quick Measurement

Measurement possible through TOF MRA only, without unnecessary settings

Quantitative Data Output
Quantitative Data Output

Statistical-based clinical research enabled
Applicable for various disease factors

Enhanced User Convenience
Enhanced User Convenience

Eliminates the need for advanced expertise, unlike traditional methods

mobile background
NeuFlow 3D Color MRA
Innovation in Cerebrovascular Diagnosis

With the world’s first FDA-approved color MRA technology,

NeuFlow goes beyond traditional 2D black-and-white imaging—offering precise cerebrovascular health diagnostics

through 3D color imaging and quantitative data, along with personalized health guidance. 

NeuFlow 처리 이미지
원본 MRA 이미지
Use NeuFlow
original
Learn more

3D Color SIG
Quantitative Analysis

The conventional black-and-white MRA is converted into 3D color imaging for hemodynamic analysis.

Vessel-specific
precision measurement

Comprehensive analysis using vessel diameter and length measurements along with hemodynamic data.

AI Health Report

Offers a cerebrovascular health score along with personalized health recommendations.

A New Standard
in Brain Health.
Experience NeuFlow.

MediImg Co., Ltd. | Est. 2018

Business License No. : 313-87-00931

Head Office: #508, SBA Hub, Mapo-gu, Seoul, Korea

R&D Center: #6, 2F, Seoul National University Hospital Healthcare Innovation Park, Bundang, Gyeonggi-do, Korea

TEL : (+82) 02-484-5773 | FAX : (+82) 02-6499-6448

E-mail : info@mediimg.com

FDA 510K Approval Date : October 15, 2024

Copyright © 2025 MEDIIMG Co., Ltd. All rights reserved.


Approved by the MFDS

MediImg Co., Ltd. | Est. 2018 

Business License No. : 313-87-00931 

Head Office: #508, SBA Hub, Mapo-gu, Seoul, Korea

R&D Center: #6, 2F, Seoul National University Hospital Healthcare Innovation Park,

Bundang, Gyeonggi-do, Korea

TEL : (+82) 02-484-5773 | FAX : (+82) 02-6499-6448 | E-mail|info@mediimg.com

FDA 510K Approval Date : October 15, 2024

Approved by the MFDS


Copyright © 2025 MEDIIMG Co., Ltd. All rights reserved.